Press Releases April 20, 2026 08:32 AM

Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026

Integra LifeSciences announces Q1 2026 earnings release and conference call scheduled for May 5, 2026.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences, a global medical technology company specializing in neurosurgery and tissue reconstruction, will release its first quarter 2026 financial results before market open on May 5, 2026. The company will hold a conference call with management to discuss the results on the same day.

Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Integra LifeSciences will publish Q1 2026 financial results on May 5, 2026, ahead of market open.
  • The management team will host a conference call and webcast to discuss the earnings.
  • The company focuses on advanced medical technologies in neurosurgery and tissue reconstruction, aiming to restore lives through innovation.

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com. 

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

Integra LifeSciences Holdings Corporation


Risks

  • Financial results may fall short of investor expectations, affecting stock price volatility.
  • Market and economic conditions in the healthcare and medical technology sectors could impact business performance.
  • Dependence on continued innovation and regulatory approvals in specialized medical fields presents ongoing uncertainties.

More from Press Releases

YY Group (NASDAQ YYGH) Launches Commercial Humanoid Robotics Initiative to Drive AI-Driven Margin Expansion and Address Global Facility Management Labor Shortages Jun 9, 2026 Shattuck Labs, Inc. Announces Proposed Public Offering Jun 9, 2026 Orchid Island Capital Announces June 2026 Monthly Dividend and May 31, 2026 RMBS Portfolio Characteristics Jun 9, 2026 Hubbell Incorporated Completes Acquisition of NSI Industries Jun 9, 2026 Correction: Precision Aerospace & Defense Group Announces Letter of Intent with Leader in Communications, Security and Surveillance Integration Solutions Jun 9, 2026